多发性骨髓瘤患者血浆白介素16水平的变化及临床意义.DOCVIP

多发性骨髓瘤患者血清IL-6与β2-MG水平的变化及临床意义 郑建洵 （福建中医药大学附属人民医院检验科 福州350004） 摘要：目的：探讨多发性骨髓瘤患者血清IL-6与β2-MG的变化及临床意义。方法：以本院2013年6月～2015年6月收治的60例多发性骨髓瘤患者为研究对象，以本院同期40例健康志愿者为对照组，用RIA法检测各组血清中IL-6与β2-MG表达水平，并随访观察。结果：MM组患者血浆IL-6、β2-MG水平均显著高于对照组，其差异均具有统计学意义（P＜0.05）。不同ISS分期的MM患者IL-16、β2-MG水平差异均具有统计学意义（P＜0.05），ISSⅢ期患者IL-6、β2-MG水平均高于ISSⅠ期和ISSⅡ期患者（P＜0.05）。MM患者初治组与复发难治组血清中IL-6、β2-MG的表达水平均明显高于对照组，且差异有统计学意义（P＜0.05）。与初治组相比，MM患者治疗有效组IL-6、β2-MG表达水平显著降低，且差异有统计学意义（P＜0.05）。MM患者复发难治组血清中IL-6、β2-MG的表达水平均明显高于初治组，且差异有统计学意义（P＜0.05）。结论：IL-6、β2-MG在多发性骨髓瘤的发生发展中起着重要作用，IL-6、β2-MG水平的升高与患者预后密切相关，可将IL-6、β2-MG作为判断多发性骨髓瘤病情评估、治疗效果和预后监测的重要指标。 关键词：多发性骨髓瘤；白介素6；β2-MG；预后；影响因素 Changes of Plasma Interleukin-6、β2-MG Levels in Patients with Multiple Myeloma and Its Clinical Significance ZHENG Jian-xun (Department of Clinical Laboratory, the Affiliated Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou350004) Abstract: Objective: To investigate the changes of plasma IL-6、β2-MG in patients with multiple myeloma and its clinical significance. Methods: Sixty patients with multiple myeloma were enrolled from June 2008 to June 2015 in our hospital. Forty healthy volunteers were selected as control group. All the patients were collected before the treatment. The levels of IL-16 and β2-MG were measured by Radioimmunoassy (RIA). Results: The levels of IL-16 and β2-MG in the MM group were significantly higher than those in the control group (P0.05). The levels of IL-16 and β2-MG in patients with ISS were significantly different (P0.05). The levels of IL-16 and β2-MG which were higher than those of ISSⅠ and ISSⅡ (P0.05). Serum IL-6 and β2-MG expression levels in first-treated group and recurrence group of paients with MM were significantly higher than those of control group, and the difference was statistically significant (P0.05). Compared with first-treated group, the IL-6 and β2-MG expression level of alleviated group were significantly lower than in the early treated group, and the difference was statistically